Study Name: SSRI versus Bupropion in High-Risk Major Depressive Disorder
Principal Investigator: Michael F. Grunebaum, M.D.
Purpose of Study: The purpose of this study is to compare two medications for the treatment of major depressive disorder and their effects on mood, suicidal thoughts, and related brain activity measured with fMRI scans.
Treatment Offered: Participants are randomly assigned to receive treatment with FDA-approved antidepressant medication, either paroxetine controlled release or bupropion extended release. Participants undergo a magnetic resonance imaging (MRI) scan before and after 8 weeks of treatment with one of these medications in order to study brain activity related to the treatment. Participants are then offered 4 additional months of antidepressant medication treatment in our clinic followed by referral to ongoing care.
Eligibility: Adults, ages 18-65, currently suffering from an episode of Major Depressive Disorder, who either have a history of past suicide attempt or are currently experiencing suicidal thoughts.
Funding: NIMH K23 Award MH076049
Contact information: Gabriella Denker